Valneva SE - ADR

NASDAQ:VALN 11:00:33 AM EDT

6.08

+0.01 (+0.16%)

4:00:10 PM EDT: $6.31 +0.23 (+3.78%)

Market Cap (Intraday)	516.97M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$50.53 Million
Adjusted EPS	-$0.39

See more estimates

10-Day MA	$5.92
50-Day MA	$6.13
200-Day MA	$5.86

See more pivots

Valneva SE - ADR Stock, NASDAQ:VALN

Campus Bio-Ouest, 6, rue Alain Bombard, Saint-Herblain, Grand Est 44800

France

Phone: +33.2.28.07.37.10

Number of Employees: 676

http://www.valneva.com

Description

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older. The DUKORAL is a drinkable vaccine that helps prevent diarrhea caused by heat-labile toxin-producing ETEC, as well as cholera. The IXCHIQ is a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.